Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry.

Biomedical chromatography : BMC - 1 Feb 2002

Werner Ulrike, Werner Dierk, Pahl Andreas, Mundkowski Ralf, Gillich Martin, Brune Kay

Abstract excerpt

A new method for the quantification of celecoxib in human plasma based on reversed-phase high-performance liquid chromatography (HPLC) coupled to atmospheric pressure chemical ionization (APCI) mass spectrometry (MS) after liquid-liquid extraction is presented. The method is rapid, sensitive and highly selective. The retention time of celecoxib was 2.3 min. The limit of quantification was 5 microg/L. Rofecoxib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclooxygenase Inhibitors

Share to Cytochrome P-450 CYP2C9

Share to Pyrazoles

Share to Reference Standards

Share to Steroid 16-alpha-Hydroxylase

Share to Steroid Hydroxylases

Source

Identifiers

PMID: 11816012
DOI: 10.1002/bmc.115

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry.PMID 11816012Read ↗

Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite.Semantic proximity Read ↗

Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.Semantic proximity Read ↗

Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.Semantic proximity Read ↗

A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1.Semantic proximity Read ↗

Integration analysis of metabolites and single nucleotide polymorphisms improves the prediction of drug response of celecoxib.Semantic proximity Read ↗

Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects.Semantic proximity Read ↗

Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants.Semantic proximity Read ↗

COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.